Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis

• Status: Recruiting
• Trial end date: 2023-02-28
• Target enrollment: 0
• Participant gender: All

Summary

This will be a systematic, combined, prospective assessment of the novel echographic, CMR, and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and after treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: IRCCS Policlinico S. Matteo

Criteria

Inclusion Criteria:

• age more than 18;

• histological diagnosis of AL amyloidosis;

• measurable cardiac involvement as per current response criteria (i.e. NT-proBNP >650 ng/L);

• measurable hematologic disease (dFLC >20 mg/L);

• adequate renal function (eGFR >30 mL/min) in order to be safely administered gadolinium;

• absence of atrial fibrillation with uncontrolled heart rate;

• absence of implantable cardiac devices;

• absence of pulmonary amyloidosis histologically documented;

• plan to start anti-plasma cell chemotherapy;

• plan to assess response at the Pavia center after 6 months;

• have given written informed consent to participate.

Exclusion Criteria:

• non-AL amyloidosis;

• NYHA class IV;

• PS-ECOG >3;

• severe allergy to paramagnetic tracer;

• severe claustrophobia;

• pregnant or nursing women;